Prof. Dr. Bernd Hoppe studierte bis 1988 Medizin an der Universität Bonn, sowie in Zürich, als auch in Adelaide (Australien). Danach startete er seine Ausbildung in Pädiatrie in verschiedenen Kliniken in Deutschland (St. Augustin, Landshut, Köln und Hannover), sowie im Kinderspital in Zürich. Sein wissenschaftliches Interesse galt schon früh der primären Hyperoxalurie.  Ein Post-Doc- (1990-1992 in Zürich, Kinderspital Pädiatrische Nephrologie), sowie ein Habilitationsstipendium (1996.-1998 in Chicago, Northwestern University, Children’s Memorial Hospital) der DFG führten zur Habilitation im Jahre 1999 zum Thema „neue Wege in Diagnostik und Therapie der primären Hyperoxalurie“.

Prof. Hoppe ist Kinderarzt, sowie Kindernephrologe und arbeitete von 1998-2012 als Oberarzt, sowie Leiter der pädiatrischen Nephrologie an der Universitätsklinik für Kinder- und Jugendmedizin in Köln. Seit September 2012 arbeitet er an der Universitätsklinik Bonn, Schwerpunkt Kindernephrologie. Derzeitige Verantwortlichkeiten schließen die Mitgliedschaft im Vorstand des europäischen Hyperoxaluriekonsortiums (OxalEurope), sowie der Oxalosis and Hyperoxaluria Foundation, USA, mit ein. Zudem ist er im medizinischen Bereit der Selbsthilfegruppe primäre Hyperoxalurie, sowie dem Verein zur Unterstützung dialysepflichtiger Kinder Renniere e.V..

Publikationen

  •  Hesse A, Thon B, Hoppe B. Vergleichsstudie zur Wirksamkeit von Allopurinol-präparationen (DabrosonR/ZyloricR-Granulat) auf die Harnszusammensetzung. Urologe B. 1989; 29:79-82
  • Hoppe B, Gnehm HP, Wopmann M, Neuhaus T, Willi U, Leumann E. Vitamin D-Intoxikationen beim Säugling: eine vermeidbare Ursache von Hypercalciurie und Nephrocalcinose. Schweiz Med Wschr. 1992;122:257-262
  • Hoppe B, Winter P, Classen A, Hesse A. Alkalisierungstherapie: Wirksame Rezidivprophylaxe bei Calciumoxalat-Lithiasis. TW Urol Nephrol. 1992;4:312-318
  • Leumann E, Hoppe B, Neuhaus T. Management of primary hyperoxaluria: Efficiacy of oral citrate administration. Pediatr Nephrol. 1993;7:207-211
  • Hoppe B, Neuhaus T, Superti A, Leumann E. Hypercalciuria and nephrocalcinosis, a feature of Wilson’s disease. Nephron. 1993;65:460-462
  • Hoppe B, Neuhaus T, Weisser B, Leumann E. Clinical quiz: Transient anuria in a newborn due to angiotensin converting enzyme inhibitor administration during pregnancy. Pediatr Nephrol. 1993;7:769-770
  • Hoppe B, Hesse A, Neuhaus T, Fanconi S, Forster Ishilde, Blau N, Leumann E. Urinary saturation and nephrocalcinosis in preterm infants: effect of parenteral nutrition. Arch Dis Child. 1993;69:299-303
  • Leumann E, Hoppe B, Neuhaus T, Blau N. Efficiacy of oral citrate administration in primary hyperoxaluria. Nephrol Dial Transplant. 1995.10 [Suppl 8]:14-16
  • Wingenfeld P, Schmidt Beate, Hoppe B, Querfeld U, Schönau E, Moritz Cordelia, Michalk D. Acute glaucoma and intracranial hypertension during growth hormone therapy in a child with long term peritoneal dialysis. Pediatr Nephrol. 1995; 9 (6):742-745
  • Hoppe B, Graf Dorothee, Offner Gisela, Latta K, Byrd DJ, Michalk D, Brodehl J. Oxalate elimination via hemodialysis or peritoneal dialysis in children with chronic renal failure. Pediatr Nephrol. 1996;10(4):488-492
  • Hoppe B, Danpure CJ, Rumsby G, Fryer P, Jennings PR, Blau N, Schubiger G, Neuhaus T, Leumann E. A vertical (pseudodominant) pattern of inheritance in the autosomal recessive disease primary hyperoxaluria type Lack of relationship between genotype, enzymic phenotype and disease severity. Am J Kidney Dis. 1997; 29(1):36-44
  • Hoppe B, Langman CB. Hypocitraturia in patients with urolithiasis. Arch Dis Child. 1997;76:175-176 (letter)
  • Pillekamp F, Hoppe B, Roth B, Querfeld U. Vomiting, headache and seizures in a child with idiopathic nephrotic syndrome. Nephrol Dial Transplant. 1997; 12:1280-1281
  • Hoppe B, Jahnen A, Bach D, Hesse A. Urinary calcium-oxalate saturation in healthy infants and children. J Urol 1997; 158:557-559
  • Müller-Berghaus J, Hoppe B, Schmidt R, Wagner M, Querfeld A transplanted child with severe hypercalcaemic hyperparathyroidism despite only modest bone lesions. Nephrol Dial Transplant 1997; 12:2445-2446
  • Hoppe B, Neuhaus T, Fanconi S, Blau N, Hesse A, Roth B, Leumann E. Influence of nutrition on urinary oxalate and calcium in preterm and term infants. Pediatr Nephrol 1997; 11(6):687-690
  • Hildebrandt F, Nothwang HG, Vossmerbäumer U, Springer C, Strahm B, Hoppe B, Keuth B, Fuchshuber A, Querfeld U, Neuhaus TJ, Brandis M and members of the APN study group. Lack of large, homozygous deletions of the nephronophtisis 1 region in Joubert syndrome type B. Pediatr Nephrol 1998; 12(1):16-19
  • Hoppe B, Hesse A, Brömme Sabine, Rietschel E, Michalk D. Urinary excretion substances in cystic fibrosis: risk of urolithiasis? Pediatr Nephrol 1998;12:275-279
  • Münch R, Brägger CP, Altorfer J, Hoppe B, Shmerling DH, Ammann R. Fecal immunoreactive lipase, a simple diagnostic test for cystic fibrosis. Europ J Pediatr 1998, 157:282-286
  • Hoppe B, Kemper MJ, Hvizd MG, Sailer DE, Langman CB. Simultaneous determination of oxalate, citrate and sulfate in children’s plasma with ion-chromatography. Kidney Int 1998; 53:1348-1352
  • Hoppe B, Kemper MJ, Bökenkamp A, Langman CB. Plasma calcium-oxalate saturation in children with renal insufficiency and in children with primary hyperoxaluria. Kidney Int 1998; 54:921-925
  • Sidhu H, Hoppe B, Hesse A, Tenbrock K, Brömme S, Rietschel E, Peck AB. Antibiotic induced loss of the gut associated bacterium oxalobacter formigines: a risk factor for hyperoxaluria in cystic fibrosis patients. Lancet 1998;352:1026-1030
  • Balla AA, Salah AM, Abdalmotaal E, Hoppe B, Bongarts D, Kessler T, Hesse A (1998) N-acetyl-ß-glucosaminidase excretion in normal and urolithiasis children. W J Urol 1998; 16:413-416
  • Hoppe B, Roth B, Bauerfeld C, Langman CB. Oxalate, citrate and sulfate concentrations in human-milk compared to formula preparations: influence on urinary anion excretion. J Pediatr Gastroent Nutr 1998;27:383-386
  • Balla AA, Salah AM, Khattab AHH, Kambal A, Bongartz D, Hoppe B, Hesse A. Mineral composition of renal stones in the Sudan. Urol Int 1998;61:154-156
  • Hoppe B, Kemper MJ, Bökenkamp A, Portale AA, Cohn RA, Langman CB. Plasma calcium-oxalate supersaturation in children with primary hyperoxaluria and end stage renal disease. Kidney Int 1999;56(1):268-274
  • Leumann E, Hoppe B. What is new in primary hyperoxaluria? Nephrol Dial Transplant 1999;14:2556-2558
  • Querfeld U, Groth W, Eder EF, Hoppe B, Sollberg S. Disseminated cutaneous plasmacellular granuloma associated with membranous glomerulonephritis. Nephrol Dial Transplant 1999;14:1268-1271
  • Neuhaus TJ, Belzer T, Blau N, Hoppe B, Sidhu H, Leumann E. Urinary oxalate excretion in urolithiasis and nephrocalcinosis. Arch Dis Child 2000;82:322-325
  • Leumann E, Hoppe B. Pre-emptive liver transplantation in primary hyperoxaluria type 1: a controversial issue. Pediatr Transplant 2000;4:161-164
  • von Buch C, Hoppe B, Lüchtrath M, Wendel U, Keuth B, Vierzig A, Roth B. Hyperammonämisches Koma bei Ornithin-Transcarbamylase-Mangel. Monatsschrift Kinderheilkunde 2000;148:997-1000
  • Hoppe B. Neue Wege in Diagnostik, Therapie und Verlaufskontrolle der primären Hyperoxalurie Typ 1. Kinder- und Jugendmedizin 2001;1:21-25
  • Hoppe Urolithiasis/Nephrokalzinose bei zystischer Fibrose. Monatsschr Kinderheilkd 2001;149:712 (Letter)
  • Gatter, N, Maier O, Hoppe B. Streptococcus pneumoniae – induced hemolytic uremic syndrome: Report of a further case. Pediatr Nephrol 2001; 16: 840 (Letter)
  • Licht C, Hell K, Eifinger F, Hoppe B, Querfeld U. Posttransplant lymphoproliferative disease in a child: clinical and molecular characterization, Pediatr Nephrol 2002; 17:79-84
  • Hoppe B, Duran I, Martin A, Kribs A, Benz-Bohm G, Michalk D, Roth B. Nephrocalcinosis in preterm infants, a single center experience. Pediatr Nephrol 2002; 17:264-268
  • Tenbrock K, Schubert A, Stapenhorst L, Kemper M, Gellermann J, Timmermann K, Müller-Wiefel DE, Querfeld U, Hoppe B, Michalk D. Type I IgE-receptor, Interleukin-4-receptor and Interleukin-13 – polymorphisms in children with nephrotic syndrome, Clin Sci 2002; 102(5):507-12.
  • Stapenhorst L, Gindele A, Hoppe B. Einseitig erweitertes Nierenbeckenkelchsystem mit kompensierter Harnabflußstörung (Bild des Monats). Monatsschr Kinderheilkd 2002;150:1402-1405
  • Hoppe B, Leumann E, von Unruh G, Laube N, Hesse A. Diagnostic and therapeutic approaches in patients with secondary hyperoxaluria. Frontiers in Biosciences 2003;8:e437-443
  • Sikora P, Roth B, Kribs A, Michalk DV, Hesse A, Hoppe B. Hypocitraturia is one of the major risk factors for nephrocalcinosis in very low birth weight (VLBW) infants. Kidney Int 2003; 63:2194-2199
  • Von Schnakenburg S, Rumsby G, Hoppe B, Latta K, Kemper M. Genetic analysis: a diagnostic tool for primary hyperoxaluria type 1. Pediatr Nephrol 2003;18:482-483
  • Sikora P, Glatz S, Beck BB, Stapenhorst L, Zajaczkowska M, Hesse A, Hoppe B. Urinary NAG in children with urolithiasis, nephrocalcinosis or risk of urolithiasis. Pediatr Nephrol, 2003; 18:996-999
  • Mehler K, Stapenhorst L, Beck B, Hoppe B. Hyperoxaluria in patients with primary distal renal tubular acidosis. Pediatr Nephrol. 2003; 18:722-723
  • Hoppe B, Langman C. A United States survey on diagnosis, treatment and outcome of patients with primary hyperoxaluria. Pediatr Nephrol, 2003; 18:986-991
  • Hoppe B, Schmidt M. Darmbakterien gegen Harnsteine. Uro-News, 2003;7(1):20-21
  • Hoppe B, Leumann E. Diagnostic and therapeutic strategies in hyperoxaluria: a plea for early intervention. Nephrol Dial Transplant, 2004; 19:39-42
  • Laube N, Hergarten S, Hoppe B, Schmidt M, Hesse A. Determination of the calcium oxalate crystallization risk from urine samples – the BONN-Risk-Index in comparison to other risk formulae. J Urol. 2004, 172:355-9.
  • Licht C, Stapenhorst L, Simon T, Schneppenheim R, Budde U, Hoppe B. Two novel ADAMTS13–gene mutations in thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome (TTP/HUS). Kidney Int, 2004; 66(3):955-958
  • Herrmann, G, Krieg T, Weber M, Sidhu H, Hoppe B. Unusual painful sclerotic like plaques on the legs of a patient with late diagnosis of primary hyperoxaluria type I. Br J Dermatol, 2004;151(5):1104-1107
  • Licht C, Weyersberg A, Heinen S, Beck B, Devenge J, Stapenhorst L, Zipfel PF, Hoppe B. Absence of Complement Factor H in Plasma Due to a Mutation in CCP Domain 15 as Cause of Atypical Hemolytic Uremic Syndrome: Successful Therapy by Plasma Infusion. Am J Kidney Dis, 2005;45(2):415-421
  • Hoopes jr. RR, Shrimpton A, Knohl SJ, Hueber P, Hoppe B, Matyus J, Simkes A, Tasik V, Thoenshof B, Suchy SF, Nussbaum RL, Scheinman SJ. Dent’s disease with mutation in OCRL1. Am J Hum Gen 2005;76(2):260-267
  • Stapenhorst L, Sassen R, Beck B, Laube N, Hesse A, Hoppe B. Hypocitraturia as a risk factor for nephrocalcinosis after kidney transplantation. Pediatr Nephrol, 2005;20(5):652-656
  • Leumann E, Hoppe B. Primary Hyperoxaluria type I: is genotyping clinically helpful? Pediatr Nephrol, 2005;20(5):555-557
  • Hoppe B, Latta K, von Schnakenburg C, Kemper MJ on behalf of the Arbeitsgemeinschaft für pädiatrische Nephrologie. Primary Hyperoxaluria: the German experience. Am J Nephrol, 2005;25(3):276-281
  • Hoppe B, von Unruh GE, Blank G, Rietschel E, Sidhu H, Laube N, Hesse A. Absorptive hyperoxaluria leads to an increased risk of urolithiasis or nephrocalcinosis in cystic fibrosis. Am J Kid Dis, 2005;46(3):440-445
  • Müller A, Beck B, Theilemann K, Stapenhorst L, Licht C, Michalk D, Franzen C, Hoppe B. Detection of Polyomavirus BK and JC in children with kidney diseases and renal transplant recipients. Pediatr Infect Dis J 2005;24:778-781
  • Laube N, Hoppe B, Hesse A. Problems in the investigation of urines from patients suffering from primary hyperoxaluria type I. Urol Res 2005; 33:394-397
  • Hoppe B, von Unruh GE, Laube N, Hesse A, Sidhu H. Oxalate degrading bacteria: new treatment option in patients with primary and secondary hyperoxaluria? Urol Res, 2005; 33:372-375
  • Straub M, Strohmeier WL, Berg W, Beck B, Hoppe B, Laube N, Lahme S, Schmidt M, Hesse A, Koehrmann KU. Diagnosis and metaphylaxis of stone disease. Consensus concept of the national working committee on stone disease fort he upcoming german urolithiasis guideline. World J Urol, 2005;23:309-323
  • Mucha B, Ozaltin F, Hinkes BG, Hasselbacher K, Ruf RG, Schultheiss M, Hangan D, Hoskins B, Schulze Everding A, Bogdanovic R, Seeman T, Hoppe B, Hildebrandt F. Mutations in the Wilms’ tumor gene cause isolated steroid resistant nephrotic syndrome and occur in Exons 8 and 9. Pediatr Res, 2006;59:325-321
  • Pieper AK, Haffner D, Hoppe B, Dittrich K, Offner G, Bonzel KE, John U, Frund S, Klaus G, Stubinger A, Duker G, Querfeld U. A randomized crossover trial comparing sevelamer with calcium acetate in children with CKD. Am J Kidney Dis. 2006;47(4):625-635
  • Stippel DL, Bangard C, Schleimer K, Koerber F, Beckurts KT, Hoppe B. Successful renal transplantation in a child with thrombosis of the inferior vena cava and both iliac veins. Transplant Proc. 2006; 38(3):688-690
  • Sayer JA, Otto EA, O’toole JF, Nurnberg G, Kennedy MA, Becker C, Hennies HC, Helou J, Attanasio M, Fausett BV, Utsch B, Khanna H, Liu Y, Drummond I, Kawakami I, Kusakabe T, Tsuda M, Ma L, Lee H, Larson RG, Allen SJ, Wilkinson CJ, Nigg EA, Shou C, Lillo C, Williams DS, Hoppe B, Kemper MJ, Neuhaus T, Parisi MA, Glass IA, Petry M, Kispert A, Gloy J, Ganner A, Walz G, Zhu X, Goldman D, Nurnberg P, Swaroop A, Leroux MR, Hildebrandt F. The centrosomal protein nephrocystin-6 is mutated in Joubert syndrome and activates transcription factor ATF4. Nat Genet. 2006;38:674-81
  • Licht C, Heinen S, Jozsi M, Loschmann I, Saunders RE, Perkins SJ, Waldherr R, Skerka C, Kirschfink M, Hoppe B, Zipfel PF. Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II). Kidney Int. 2006;70:42-50.
  • Beck B, Hoppe B. Is there a genotype-phentype correlation in primary hyperoxaluria type 1? Kidney Int 2006;70:984-986
  • Hoppe B, Beck B, Gatter N, von Unruh G, Tischer A, Hesse A, Laube N, Kaul P, Sidhu H. Oxalobacter formigenes: a potential tool for the treatment of primary hyperoxaluria type 1. Kidney Int 2006;70(7):1305-11
  • Utsch B, Bokenkamp A, Benz MR, Besbas N, Dotsch J, Franke I, Frund S, Gok F, Hoppe B, Karle S, Kuwertz-Broking E, Laube G, Neb M, Nuutinen M, Ozaltin F, Rascher W, Ring T, Tasic V, van Wijk JA, Ludwig M. Novel OCRL1 mutations in patients with the phenotype of Dent disease. Am J Kidney Dis. 2006;48(6):942
  • Licht C, Schlotzer-Schrehardt U, Kirschfink M, Zipfel PF, Hoppe B. MPGN II – genetically determined by defective complement regulation? Pediatr Nephrol. 2007 Jan;22(1):2-9
  • Wolf MT, Beck BB, Zauke F, Kunze A, Misselwitz J, Ruley J, Ronda T, Fischer A, Eifinger F, Licht C, Otto E, Hoppe B, Hildebrandt F. The Uromodulin C744G mutation cuases MCKD2 and FJHN in children and adults and may be due to a possible founder effect. Kidney Int 2007; 71(6):574-81
  • Dorbecker C, Licht C, Korber F, Plum G, Haefs C, Hoppe B, Seifert H. Community-acquired pneumonia due to Bordetella holmesii in a patient with frequently relapsing nephrotic syndrome. J Infect. 2007;54:203-5
  • Gatter N, Michalk D, Hoppe B. Das nephrotische Syndrom. Pädiatr Praxis 2006/2007;69:643-658
  • Hoppe B. Früherkennung bei (genetisch bedingter Steinerkrankung) im Kindesalter. Uro News 2007, 8:31-35
  • Gatter N, Hoppe B, Nutzenadel F, Waldherr R, Querfeld U. A cutaneous disease with multisystem involvement: hypomelanosis of Ito may be associated with proteinuria, focal segmental glomerulosclerosis and end-stage renal disease. Nephrol Dial Transplant 2007;22(6):1796-8.
  • Zipfel PF, Edey M, Heinen S, Jozsi M, Richter H, Misselwitz J, Hoppe B, Routledge D, Strain L, Hughes AE, Goodship JA, Licht C, Goodship TH, Skerka C. Deletion of Complement Factor H-Related Genes CFHR1 and CFHR3 Is Associated with Atypical Hemolytic Uremic Syndrome. PLoS Genet. 2007;16;3(3):e41
  • Beck BB, Habbig S, Hoppe B. Pathophysiologie kindlicher Steinerkrankungen: Ursache unbedingt abklären. Ärztl Praxis Urol 2008;1:24-26
  • Beck BB, Habbig S, Hoppe B. Harnsteine bei Kindern. Ärztl Praxis Urol 2008;8-10
  • Sikora P, von Unruh GE, Beck B, Feldkötter M, Zajączkowska M, Hesse A, Hoppe B. [(13)C(2)]oxalate absorption in children with idiopathic calcium oxalate urolithiasis or primary hyperoxaluria. Kidney Int. 2008;73(10):1181-6.
  • Beck BB, Laube N, Habbig S, Feldkötter M, Fries JWU, Hoppe B. The case: A boy with frequent recurring stones to right later to the left kidney. Kidney Int. 2008 Jul;74(1):133-4
  • Beck B, Habbig S, Hoppe B. Urolithiasis: Handlungsbedarf auch ohne Symptome. Ärtzl Praxis Urol 2008;2:31-33
  • Tasic V, Korneti P, Gucev Z, Hoppe B, Blau N, Cheong HI. Atypical presentation of distal renal tubular acidosis in two siblings. Pediatr Nephrol. 2008;23(7):1177-1181.
  • Müller-Berghaus J, Kemper MJ, Hoppe B, Querfeld U, Müller-Wiefel DE, Morahan G, Schadendorf D, Tenbrock K. The clinical course of steroid-sensitive childhood nephrotic syndrome is associated with a functional IL12B promoter polymorphism. Nephrol Dial Transplant. 2008 Dec;23(12):3841-4. Epub 2008 Jul 15.
  • Habbig S, Mihatsch MJ, Heinen S, Beck B, Emmel M, Skerka C, Kirschfink M, Hoppe B, Zipfel PF, Licht C. C3 deposition glomerulopathy due to a functional Factor H defect. Kidney Int. 2009 Jun;75(11):1230-4. Epub 2008 Jul 16.
  • Stapenhorst L, Hesse A, Hoppe B. Hyperoxaluria after ethylene glycol poisoning. Pediatr Nephrol 2008;23(12):2277-2279
  • Offner G, Toenshoff B, Höcker B, Krauss M, Bulla M, Cochat P, Fehrenbach H, Fischer W, Foulard M, Hoppe B, Hoyer PF, Jungraithmayr TC, Klaus G, Latta K, Leichter H, Mihatsch MJ, Misselwitz J, Montoya C, Müller-Wiefel DE, Neuhaus TJ, Pape L, Querfeld U, Plank C, Schwarke D, Wygoda S, Zimmerhackl LB. Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids. 2008;86(9):1241-8
  • Höcker B, Kovarik JM, Daniel V, Opelz G, Fehrenbach H, Holder M, Hoppe B, Hoyer P, Jungraithmayr TC, Köpf-Shakib S, Laube GF, Müller-Wiefel DE, Offner G, Plank C, Schröder M, Weber LT, Zimmerhackl LB, Tönshoff B.Pharmacokinetics and immunodynamics of basiliximab in pediatric renal transplant recipients on mycophenolate mofetil comedication. Transplantation. 2008 Nov 15;86(9):1234-40.
  • Dietrich A, Matejas V, Bitzan M, Hashmi S, Kiraly-Borri C, Lin SP, Mildenberger E, Hoppe B, Palm L, Shiihara T, Steiss JO, Tsai JD, Vester U, Weber S, Wühl E, Zepf K, Zenker M. Analysis of genes encoding laminin beta2 and related proteins in patients with Galloway-Mowat syndrome. Pediatr Nephrol 2008;23:1779-86
  • Wolf MT, Hoskins BE, Beck BB, Hoppe B, Tasic V, Otto EA, Hildebrandt F. Mutation analysis of the Uromodulin gene in 96 individuals with urinary tract anomalies (CAKUT). Pediatr Nephrol 2009;24:55-60
  • Markert E, Siebolts U, Habbig S, Odenthal M, Dienes HP, Stippel DL, Hoppe B, Wickenhauser C. Evolution of PTLD following renal transplantation in a child. Pediatr Transplant. 2009 May;13(3):379-83. Epub 2008 Oct 7.
  • Hoppe B, Kemper MJ. Diagnostic examination of the child with urolithiasis or nephrocalcinosis. Pediatr Nephrol. Pediatr Nephrol. 2010 Mar;25(3):403-13 [Epub 2008 ahead of print]
  • Sikora P, Beck B, Zajączkowska M, Hoppe B. Plasma oxalate level in pediatric calcium stone formers with or without secondary hyperoxaluria. Urol Res. 2009 Apr;37(2):101-5. Epub 2009 Jan 30.
  • Hoppe B, Beck BB, Milliner DS. The primary hyperoxalurias. Kidney Int. 2009 Jun;75(12):1264-71. Epub 2009 Feb 18.
  • Habbig S, Beck B, Feldkötter M, Körber F, Laffeber C, Verkoelen C, Mihatsch M, Hoppe B. Renal allograft calcification – prevalence and etiology in pediatric patients. Am J Nephrol. 2009 Apr 30;30(3):194-200. [Epub ahead of print]
  • Brinkert F, Ganschow R, Helmke K, Harps E, Fischer L, Nashan B, Hoppe B, Kulke S, Müller-Wiefel DE, Kemper MJ. Transplantation procedures in children with primary hyperoxaluria type 1: outcome and longitudinal growth. Transplantation. 2009 May 15;87(9):1415-21.
  • Wu F, Reed AA, Williams SE, Loh NY, Lippiat JD, Christie PT, Large O, Bettinelli A, Dillon MJ, Goldraich NP, Hoppe B, Lhotta K, Loirat C, Malik R, Morel D, Kotanko P, Roussel B, Rubinger D, Schrander-Stumpel C, Serdaroglu E, Nesbit MA, Ashcroft F, Thakker RV. Mutational Analysis of CLC-5, Cofilin and CLC-4 in Patients with Dent’s Disease. Nephron Physiol. 2009 Jun 20;112(4):p53-p62. [Epub ahead of print]
  • Bökenkamp A, Böckenhauer D, Cheong HI, Hoppe B, Tasic V, Unwin R, Ludwig M. Dent-2 disease: a mild variant of Lowe syndrome. J Pediatr. 2009 Jul;155(1):94-9.
  • Sikora P, Zajączkowska M, Hoppe B. Assessment of crystallization risk formulas in pediatric calcium stone-formers. Pediatr Nephrol. 2009 Oct;24(10):1997-2003. Epub 2009 Mar 31.
  • Köhrmann KU, Knoll T, Chaussy C, Fahlenkamp D, Haupt G, Hofmann R, Janitzky V, Jocham D, Lahme S, Lebentrau S, Neisius D, Oehlschläger S, Rassweller J, Türk C, Wilbert D, Straub M, Berg W, Hesse A, Laube N, Schmidt M, Strohmaler WL, Hoppe B. S2 guidelines on diagnostic, therapy and metaphylaxis of urolithiasis. Part 2: Metabolic diagnostic and metaphylaxis. Arbeitskreis Harnsteine der Akademie der Deutschen Urologen; Arbeitskreis Endourologie und Steinerkrankung der Osterreichischen Gesellschaft für Urologie. Urologe A. 2009 Sep;48(9):1084-93
  • Licht C, Pluthero FG, Li L, Christensen H, Habbig S, Hoppe B, Geary DF, Zipfel PF, Kahr WH. Platelet-associated complement factor H in healthy persons and patients with atypical HUS. Blood. 2009 Nov 12;114(20):4538-45. Epub 2009 Aug 24
  • Sullivan M, Erlic Z, Hoffmann MM, Arbeiter K, Patzer L, Budde K, Hoppe B, Zeier M, Lhotta K, Rybicki LA, Bock A, Berisha G, Neumann HP. Epidemiological approach to identifying genetic predispositions for atypical hemolytic uremic syndrome. Ann Hum Genet. 2010 Jan;74(1):17-26.
  1. Habbig S, Beck BB, Hoppe B. Nephrocalcinosis and urolithiasis in children. Kidney Int. 2011 Dec;80(12):1278-91. doi: 10.1038/ki.2011.336. Epub 2011 Sep 28.
  1. Beck BB, Habbig S, Dittrich K, Stippel D, Kaul I, Koerber K, Goebel H, Salido EC, Kemper M, Meyburg J, Hoppe B. Liver cell transplantation in severe infantile oxalosis – a possible bridging procedure? Nephrol Dial Transplant. 2012 Jan 28. [Epub ahead of print]
  2. Hoppe B, Schaar B. The impact of nutrition and physical activity on long-term survival after pediatric solid organ transplantation. Pediatr Transplant. 2012 Feb 21. doi: 10.1111/j.1399-3046.2012.01663.x. [Epub ahead of print] No abstract available.
  • Loos S, Ahlenstiel T, Kranz B, Staude H, Pape L, Härtel C, Vester U, Buchtala L, Benz K, Hoppe B, Beringer O, Krause M, Müller D, Pohl M, Lemke J, Hillebrand G, Kreuzer M, König J, Wigger M, Konrad M, Haffner D, Oh J, Kemper MJ. An Outbreak of Shiga Toxin-Producing Escherichia coli O104:H4 Hemolytic Uremic Syndrome in Germany: Presentation and Short-term Outcome in Children. Clin Infect Dis. 2012 Jul 5. [Epub ahead of print]
  • Hoppe B. The enzyme 4-hydroxy-2-oxoglutarate aldolase is deficient in primary hyperoxaluria type III (editorial comment), Nephrol Dial Transplant, Nephrol Dial Transplant . 2012 Aug;27(8):3024-6
  • Hoppe B. An update an primary hyperoxaluria, Nat Rev Nephrol. 2012 Jun 12;8(8):467-75. doi: 10.1038/nrneph.2012.113. [Epub ahead of print]
  1. Beck BB, Baasner A, Buescher A, Habbig S, Reintjes N, Kemper MJ, Sikora P, Mache C, Pohl M, Stahl M, Toenshoff B, Pape L, Fehrenbach H, Jacob DE, Grohe B, Wolf MT, Nürnberg G, Yigit G, Salido EC, Hoppe B. Novel findings in patients with primary hyperoxaluria type III and implications for advanced molecular testing strategies. Eur J Hum Genet. 2012 Jul 11. doi: 10.1038/ejhg.2012.139. [Epub ahead of print]
 Schalk G, Kirschfink M, Wehling C, Gastoldi S, Bergmann C, Hoppe B, Weber LT.A complicated case of atypical hemolytic uremic syndrome with frequent relapses under eculizumab.Pediatr Nephrol. 2015 Jun;30(6):1039-42. doi: 10.1007/s00467-015-3078-6. Epub 2015 Mar 10
Matoussevitch V, Taylan C, Konner K, Gawenda M, Kuhr K, Hoppe B, Brunkwall J. AV fistula creation in paediatric patients: outcome is independent of demographics and fistula type reducing usage of venous catheters. J Vasc Access. 2015 Sep-Oct;16(5):382-7. doi: 10.5301/jva.5000395. Epub 2015 May 30
Kurt-Sukur ED, Özçakar ZB, Fitöz S, Yilmaz S, Hoppe B, Yalçinkaya F. Primary Hyperoxaluria Type 1: A Cause for Infantile Renal Failure and Massive Nephrocalcinosis. Klin Padiatr. 2015 Sep;227(5):293-5. doi: 10.1055/s-0035-1554638. Epub 2015 Jun 19.
Oosterveld MJ, Garrelfs MR, Hoppe B, Florquin S, Roelofs JJ, van den Heuvel LP, Amann K, Davin JC, Bouts AH, Schriemer PJ, Groothoff JW. Eculizumab in Pediatric Dense Deposit Disease. Clin J Am Soc Nephrol. 2015 Oct 7;10(10):1773-82. doi: 10.2215/CJN.01360215. Epub 2015 Aug 27. 

Ganschow R, Hoppe B. Review of combined liver and kidney transplantation in children.Pediatr Transplant. 2015 Dec;19(8):820-6. doi: 10.1111/petr.12593. Epub 2015 Sep 9. Review.

Schaefer F, Hoppe B, Jungraithmayr T, Klaus G, Pape L, Farouk M, Addison J, Manamley N, Vondrak K. Safety and usage of darbepoetin alfa in children with chronic kidney disease: prospective registry study. Pediatr Nephrol. 2015 Oct 19

Kreuzer M, Prüfe J, Oldhafer M, Bethe D, Dierks ML, Müther S, Thumfart J, Hoppe B, Büscher A, Rascher W, Hansen M, Pohl M, Kemper MJ, Drube J, Rieger S, John U, Taylan C, Dittrich K, Hollenbach S, Klaus G, Fehrenbach H, Kranz B, Montoya C, Lange-Sperandio B, Ruckenbrodt B, Billing H, Staude H, Heindl-Rusai K, Brunkhorst R, Pape L.Transitional Care and Adherence of Adolescents and Young Adults After Kidney Transplantation in Germany and Austria: A Binational Observatory Census Within the TRANSNephro Trial.Medicine (Baltimore). 2015 Dec;94(48):e2196.

Weigel F, Lemke A, Tönshoff B, Pape L, Fehrenbach H, Henn M, Hoppe B, Jungraithmayr T, Konrad M, Laube G, Pohl M, Seeman T, Staude H, Kemper MJ, John U. Febrile urinary tract infection after pediatric kidney transplantation: a multicenter, prospective observational study.Pediatr Nephrol. 2016 Jan 11.